Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access.

“With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more than ever,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Kathleen has built and led these functions at scale across multiple biopharma organizations, and she brings the perspective we need as we work to potentially deliver a new treatment option to people living with treatment-resistant depression. We are delighted to welcome her to the Board.”

Ms. Tregoning most recently served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, where she guided the company through a period of significant growth, culminating in its acquisition by AbbVie in 2024. Previously, she served as Executive Vice President, External Affairs at Sanofi, where she led an integrated organization overseeing global market access, public policy, government affairs, communications, patient advocacy and corporate social responsibility.

Prior to Sanofi, Ms. Tregoning spent more than a decade at Biogen in corporate affairs. Earlier in her career, Ms. Tregoning served as a professional staff member in the United States Congress, holding health policy roles across various committees. She currently serves on the Board of Directors of Spero Therapeutics, Inc. (Nasdaq: SPRO). Ms. Tregoning earned a B.A. in International Relations from Stanford University and an M.A. in Public Policy from the Harvard Kennedy School.

Schreibe Deinen Kommentar